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Abstract Cord red cell membranes express many differentia-
tion-related molecules. To study such molecules, we have
established human cell lines, termed GL-1 and GL-2, by the
Epstein^Barr virus transformation method, both of which
produce monoclonal anti-i cold agglutinin [Y. Nagatsuka et al.,
Immunol. Lett. 46 (1995) 93^100]. Thin layer chromatography
immunoblotting analysis revealed that these antibodies had broad
specificities reacting with a variety of glycolipid antigens. Of the
immunoreactive lipid antigens, a new phosphoglycerolipid con-
taining glucose from human cord red cells was found. The
isolated lipid was unstable to alkaline hydrolysis and contained
glucose as a sole sugar. Secondary ion mass spectrum^collision-
induced dissociation mass spectrometric analysis of this lipid
gave the main molecular ion peak at m/z 885 corresponding to
phosphatidylhexose. This antigen was susceptible to phospholi-
pases A2, C and D but resistant to phosphatidylinositol-specific
phospholipase C. Two-dimensional nuclear magnetic resonance
spectroscopy confirmed that glucose is linked to the sn-glycerol
3-phosphate residue with a L-anomeric configuration. Based
upon these combined results, we identified this lipid as
phosphatidyl-L-D-glucose. This is the first report showing the
presence of the glucosylated glycerophospholipid in mammalian
sources. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Natural autoantibodies generally consist of IgM immuno-
globulins encoded by germline genes displaying ‘multi-reactiv-
ity’ with low a⁄nity towards a wide range of antigens (for
review, see [1]). Anti-i cold agglutinins belong to such natural
autoantibodies mostly of the IgM class (for review, see [2]),
which are encoded by the VH4-21 gene [3^5]. The i antigens
include carbohydrate moieties of glycoproteins or glycolipids
containing repeating N-acetyllactosamine units as its determi-
nant [6^8]. However, the same IgM antibodies have been re-
ported to be cross-reactive even with DNA and lipid A of
Gram-negative bacteria [9,10]. Though the a⁄nity to individ-
ual antigens is low, such antibodies are considered to play a
physiological role in early defense mechanisms.
To study di¡erentiation-related antigens, we previously es-
tablished two human B-cell lines, GL-1 and GL-2, both pro-
ducing anti-i antibodies (mAbs) [11]. By using the mAbs, we
found that a glycolipid antigen expressed in an Epstein^Barr
virus (EBV)-negative B-cell line is down-modulated by EBV
infection [12]. Unexpectedly, we have found that the target
antigen of the B-cell line was not an i-active glycolipid but
an alkaline labile glycolipid possessing 9-O-acetylated sialic
acid [12]. However, in the case of human cord red cells, during
puri¢cation of antigenic lipids, we noticed the presence of
another immunoreactive lipid with a similar behavior to phos-
phatidylinositol on thin layer chromatographic (TLC) analy-
sis.
To determine the chemical structure of the mAb GL-1/GL-
2-reactive antigen, we isolated the major antigenic lipid from
cord red cells with monitoring by TLC immunostaining. Here
we identify one of the major immunoreactive compounds as
phosphatidylglucose.
2. Materials and methods
2.1. Monoclonal antibody
Human mAbs GL-1 and GL-2 were prepared with EBV transfor-
mation as previously described [11]. In this report, we mainly used
mAb GL-2.
2.2. Extraction and partial puri¢cation of antigenic lipid from cord red
cells
Human cord blood was collected under sterile conditions and im-
mediately lyophilized because a preliminary result had shown that
both red cells and serum contained the immunoreactive lipid though
the contents in red cells were higher than in serum. We used whole
cord blood in this experiment to obtain as much antigenic lipid as
possible. The total lipid was extracted from the pooled lyophilized
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powder (496 g) with chloroform (C):methanol (M) (2:1, v/v), twice,
then C:M:water (W) (5:8:3, v/v), twice. The extracts were combined,
evaporated, dialyzed against water, then lyophilized. Approximately
one-¢fth of the lyophilized extract obtained was applied onto a Q-
Sepharose column (2.5U60 cm) which was pre-equilibrated with
C:M:W (30:60:8, v/v). The column was washed with the same solvent
to remove the neutral lipids, then Q-Sepharose-retained materials
were eluted with a gradient from 200 ml C:M:W (30:60:8, v/v) to
200 ml C:M:1 M aqueous sodium acetate (30:60:8, v/v). Elution was
monitored on TLC with resorcinol spray and TLC immunostaining
with mAb GL-2. The immunoreactive fractions were pooled, evapo-
rated and dialyzed against water, then lyophilized. The sample was
treated with phosphatidylinositol-speci¢c phospholipase C (PI-PLC)
according to the method of Ikezawa et al. [13]. The PI-PLC digest was
dialyzed against water, lyophilized, and dissolved in C:M (9:1, v/v),
then loaded onto a phenylboronate agarose (PBA 60, Millipore Cor-
poration, USA) column which was pre-equilibrated with C:M (9:1,
v/v). The column was washed with ¢ve column volumes of C:M (9:1,
v/v) and with a column volume of C:M (2:1, v/v) (PB-1). The PBA-
retained materials were then eluted by ¢ve column volumes of
C:M:W (5:5:1, v/v) (PB-2). The PB-2 fraction was dialyzed against
water, then applied onto a Senshu-pack Aquasil HPLC column (Sen-
shu-Kagaku, Japan) and the immunoreactive lipid was eluted with a
gradient from C:M:W 60:20:0.5 (v/v) to C:M:W 60:25:1 (v/v). Elu-
tion was monitored by TLC immunostaining and the immunoreactive
fraction was pooled.
2.3. TLC immunostaining
TLC immunostaining was performed according to the method of
Higashi et al. [14,15] except that the 3,3P-diaminobenzidine tetrahy-
drochloride kit (ICN Biochemicals, Inc., USA) with sensitizing by the
addition of 1 mM NiCl2 was used as chromogenic substrate.
2.4. Two-dimensional TLC
The partially puri¢ed antigen was spotted onto the origin of the
TLC plate Polygram Sil G (Macherey-Nagel, Germany). 2D TLC was
developed twice with the following solvent mixtures for each direc-
tion. The TLC was developed with a solvent system of C:M:aqueous
12 mM MgCl2 (60:35:8, v/v) as the ¢rst solvent, then it was developed
with C:acetone (A):M:acetic acid (HOAc):W (3:4:1:1:0.5, v/v) [16]
as the second solvent for the ¢rst dimension. After being well dried, it
was developed with C:M:20% aqueous ammonia (60:35:8, v/v) as the
¢rst solvent and C:A:M:HOAc:W (3:4:1:1:0.5, v/v) as the second
solvent for the second dimension.
2.5. TLC blotting and mass spectrometry
The immunoreactive lipid separated on the 2D TLC was transferred
onto a PVDF membrane by the TLC blotting technique [17,18]. Then
it was applied to negative secondary ion mass spectrometry (SIMS) by
a TSQ 70 triple quadrupole mass spectrometer (Finnigan MAT, USA)
[17,19].
2.6. Hexose analysis
The marked spot on the PVDF membrane blot was cut and ex-
tracted twice with a small volume of C:M (2:1, v/v). The extract was
dried and then methanolized with 5% HCl^methanol at 80‡C for 2 h.
After nitrogen gas £ushing, the sample was trimethylsilylated by the
addition of 20 Wl of trimethylsilylimidazole and 200 Wl of pyridine,
then applied to an OV-17 column equipped with a gas mass spectrom-
eter (Finnigan-MAT, USA) and analyzed by raising the temperature
from 100‡C to 250‡C at a rate of 5‡C/min.
2.7. Nuclear magnetic resonance (NMR) spectrum
The immunoreactive lipid on the 2D TLC was scraped. The silica
gel powder was packed into a small column (4U4 mm) and eluted
with C:M (2:1, v/v) and C:M:W (5:5:1, v/v). After evaporation of
the solvent by centrifugal vacuum evaporation, the lipid was dissolved
into d6-dimethyl sulfoxide and the 2D FG total correlation spectros-
copy (TOCSY) spectrum was obtained by a JEOL K-600 NMR spec-
trometer.
2.8. Quantitative determination of phosphatidylglucose in cord red cells
The amount of phosphatidylglucose was calculated by phosphorus
Fig. 1. a: TLC immunostaining of cord (lanes 1 and 2) and adult (lanes 3 and 4) red cell whole lipid extracts (erythrocyte volume 0.1 ml equiv-
alent) with mAb GL-2. Lanes 1 and 3, PB-1; lanes 2 and 4, PB-2. Lane 5, standard i-ganglioside (prepared from bovine erythrocytes contain-
ing over 90% of i-ganglioside); lane 6, standard ganglioside mixture, containing GM3, GM2, GM1, GD1a, GD1b, GT1b. b: The major immu-
noreactive lipid (indicated by an arrow in the chromatogram) was eluted in the ganglioside fraction on a Q-Sepharose column. Spots were
visualized by resorcinol^HCl followed by orcinol^H2SO4 reagent. c: The elution pro¢le of immunoreactive lipid from the same column deter-
mined by TLC immunostaining. The immunoreactive fractions were pooled, dialyzed against water, and lyophilized, then used for further anal-
ysis.
Fig. 2. Separation of the immunoreactive compound and PI on 2D
TLC. A part of the Senshu-pack HPLC immunoreactive fraction
was spotted onto the origin of the TLC plate and developed as de-
scribed in Section 2. The standard lane was cut o¡ and PI was de-
tected under UV light after spraying pulimurin reagent. Standard
gangliosides were visualized by resorcinol spray. The sample area
was stained with mAb GL-2, and the immunoreactive spot was de-
tected by peroxidase-conjugated anti-human Igs using Ni-sensitized
diaminobenzidine substrate.
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content determined with the method of Bartlett [20] and glucose con-
tents assayed by gas chromatography (described in Section 2.7).
3. Results
3.1. Occurrence of mAb GL-2 reactive lipid antigens in human
cord red cells
We isolated the anti-i cold agglutinin, mAb GL-2, as de-
scribed previously [11]. These mAbs agglutinate human cord
red cells but not adult red cells on ice but not at room temper-
ature. The minimal amount of IgM protein required for cord
red cell agglutination was 12.5 ng. The mAbs immunostained
several lipids in the PBA-retained fraction (PB-2) from cord
red cells. The reactive lipids were greatly reduced in adult red
cell lipids on TLC, as shown in Fig. 1a. The major immuno-
reactive lipid was partially puri¢ed on a Q-Sepharose column
(Fig. 1b,c). The immunoreactive lipid (indicated by an arrow
in the ¢gure) was eluted slightly after the major ganglioside
GM3 and slightly before sialylparagloboside. The immunore-
active fraction on Q-Sepharose was pooled and used as a
starting material for further puri¢cation and structural anal-
ysis as described below.
3.2. Isolation and characterization of a major immunoreactive
compound
To characterize the structure of immunoreactive lipids, we
further puri¢ed a major immunoreactive compound from the
Q-Sepharose fraction by PBA and Iatrobeads column chro-
matographies. The immunoreactive compound thus obtained
showed a single spot on TLC determined with resorcinol fol-
lowed by orcinol reagent. Then, the lipid was subjected to
negative SIMS^collision-induced dissociation (CID) mass
spectrometric analysis. A major molecular ion peak was ob-
served at m/z 885 corresponding to phosphatidylinositol (Fig.
3) [21,22]. However, the antigenic lipid was insensitive to PI-
PLC although it was susceptible to phospholipase (PL) A, C
and D.
Since there was a possibility that PI was present in the
Iatrobeads fraction, we removed the contaminant PI in the
Q-Sepharose fraction by extensive treatment with PI-PLC.
The resultant lipid fraction was puri¢ed by PBA and Sen-
shu-pack Aquasil HPLC column chromatographies. However,
the puri¢ed lipid gave the same molecular ion peak at m/z 885.
To further con¢rm that the immunoreactive lipid is di¡er-
ent from PI, we developed a solvent system to separate PI and
Fig. 3. Secondary ion mass spectra of the lipid puri¢ed form cord red cells (a^c) and PI (d^f). The immunoreactive lipid separated by 2D TLC
was blotted onto a PVDF membrane and recovered from the blotted membrane. a,d: Total SIMS pattern. b,e and c,f: Spectra derived from
m/z 885 and m/z 863, respectively.
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the immunoreactive lipid on TLC. The immunoreactive frac-
tion from Senshu-pack was analyzed by 2D TLC as described
in Section 2. Fig. 2 shows clearly that the immunoreactive
lipid moved faster than authentic PI in the second dimension.
3.3. SIMS with direct TLC blotting from immunostained TLC
plates
To obtain the SIMS^CID spectrum of the immunoreactive
spot itself, we blotted the spot shown in Fig. 2 directly onto
Fig. 4. Hexose analysis of the immunoreactive spot by GC-MS. The immunoreactive spot on the 2D TLC was blotted directly onto the PVDF
membrane, and the blotted spot was cut o¡, extracted twice with C:M (2:1, v/v), evaporated, and then methanolized with 5% HCl^methanol
at 80‡C for 2 h. The obtained methylglycoside was trimethylsilylated with trimethylsilylimidazole and analyzed by gas chromatography. The
methylglycosides of authentic glucose, galactose and inositol were similarly trimethylsilylated and used as standards.
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the PVDF membrane and analyzed it by SIMS^CID mass
spectrometry. As shown in Fig. 3a, the most abundant neg-
ative molecular ion was again observed at m/z 885. The
SIMS^CID spectra of m/z 863 and 885 are also shown in
Fig. 3b,c. Both molecules gave a fragment ion at m/z 581
corresponding to its lyso-species. A fragment ion at m/z 419
was lysophosphatidic acid. A fragment ion at m/z 283 was
fatty acid, C18:0 at the C1 position. Fatty acids at the C2
position were observed at m/z 281 and 303 corresponding to
C18:1 and C20:4 derived from [M3H]3 863 and 885, respec-
tively. Hexose phosphate and hexose phosphate minus H2O
were observed at m/z 241 and 223, respectively. The presence
of PO33 and H2PO
3
4 was con¢rmed by fragment ions at m/z 79
and 97. The SIMS^CID spectra of the immunoreactive lipid
are very similar to that of authentic PI, as shown in Fig. 3d^f.
Thus, the immunoreactive lipid has the same backbone struc-
ture as PI and contained hexose instead of inositol.
Fig. 5. 2D TOCSY spectrum of phosphatidylglucose. A 600 MHz TOCSY spectrum of phosphatidylglucose was measured in a solution of
d-DMSO at 25‡C, mixing time of 50 ms. In the spectrum, Glc, Gly and FA indicate protons on the L-Glc, glycerol and fatty acid double
bonds, respectively. Approximately 150 Wg of phosphatidylglucose was applied.
Table 1
Chemical shift and coupling constant of glucose and glycerol of
phosphatidylglucose
Position Chemical shift (ppm) Coupling (Hz)
Glucose C1 4.20 d (8.4)
Glucose C2 2.89 t (7.5)
Glucose C3, 4 and 5 3.08 ND
Glucose C6a 3.54 t (7.6)
Glucose C6b 3.75 ND
Glycerol C1 4.06 q (6.7)
Glycerol C1P 4.27 q (9.0; 3.0)
Glycerol C2 5.05 ND
Glycerol C3 3.70 ND
Glycerol C3P 3.81 q (4.6)
ND: not de¢ned. Chemical shifts of the C1^C6 protons of glucose
and the C1^C3 protons of glycerol were determined from the 2D
TOCSY spectrum with a mixing time of 50 ms.
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3.4. The immunoreactive compound contains glucose but not
inositol as hexose
To determine the hexose species, the immunoreactive com-
pound was extracted from the blots and analyzed as described
in Section 2. The immunoreactive compound contained glu-
cose, but neither inositol nor galactose (Fig. 4). This result
indicates that the immunoreactive compound is a phosphogly-
cerolipid containing glucose linked to phosphatidic acid, that
is ‘phosphatidylglucose’.
3.5. NMR spectrum of the immunoreactive lipid
For further con¢rmation of the structure of phosphatidyl-
glucose, the lipid as subjected to NMR 2D TOCSY analysis.
An anomeric proton of glucose was assigned at N= 4.2 ppm
and a coupling constant J1;2 value of 8.4 Hz revealed that the
antigenic molecule contains glucose with a L-anomeric con¢g-
uration (Fig. 5 and Table 1) whereas the standard K-D-glu-
cose-1-phosphate showed an anomeric proton at N= 5.45 ppm
and a coupling constant J1;2 value of 7.6 and 4.0 Hz. The PI
C1 proton has been reported as N= 3.9 ppm and a J1;2 value
of 2.7 Hz [23]. Combining all these results, one of the major
cord red cell lipid antigens reacting with mAb GL-1/GL-2 was
identi¢ed as phosphatidyl L-D-glucose (Fig. 6).
3.6. Level of phosphatidylglucose in cord red cells
The amount of phosphatidylglucose in cord red cells was
estimated based upon phosphorus analysis of immunostained
TLC. The approximate amount of phosphatidylglucose was
estimated to be 10 nmol/g dried red cells, determined by the
phosphorus contained in the immunoreactive spot, whereas
the amount of phosphatidylinositol was approximately
3 nmol. The yields of glucose and phosphorus in the ¢nal
product were 2.2 and 3.1 nmol/g dried red cells (molar ratio
1:1.4), respectively.
4. Discussion
Natural antibodies are often multi-reactive. A⁄nities to in-
dividual antigens are generally low but they recognize a wide
range of antigens. For example, Bohn et al. [24] obtained
human mAbs, which bind to tumor cells to inhibit cell
growth, from a non-tumor-associated patient. This mAb
also reacts with tetanus toxin or DNA, which is not expressed
on the surface of tumor cells. Such antibodies have been dis-
regarded because their speci¢cities were very low and accord-
ingly they were not applicable as immunobiochemical re-
agents. However, Avrameas [25] and Coutinho et al. [1]
described the biological signi¢cance of natural autoantibodies.
They play roles (1) in removal of senescent/altered self com-
ponents, (2) as the ¢rst line of natural defense against infec-
tious agents, (3) as immune regulatory factors through idio-
typic networks, and (4) as a platform for antigen-speci¢c
immune responses from which strictly speci¢c ‘immune anti-
bodies’ are derived by selective pressure of foreign antigens.
‘Phosphatidylglucose’ has been reported in a few microbes.
Smith and Henrickson [26] have reported a glucose-containing
phospholipid in Mycoplasma laidlawii strain B whose infrared
spectrum possessed some resemblance to that of PI and they
reported it as phosphatidylglucose. However, this lipid was
resistant to PLA, PLC and PLD digestion. Later, Shaw et
al. [27] proposed that the M. laidlawii lipid is not phosphati-
dylglucose but glycerylphosphoryldiglucosyl diglyceride. Short
and White [28] isolated two glucose-containing phospholipids
from Staphylococcus aureus and identi¢ed one of them as
phosphatidylglucose, which was sensitive to PLC and PLD.
The possibility that phosphatidylglucose is derived from
bacterial contamination in cord blood is unlikely because
the cord blood was taken under sterile conditions and imme-
diately frozen before use. In addition, phosphatidylglucose
was always detected when the lipid was prepared and ana-
lyzed from each small-scale sample. Furthermore, no bacterial
endotoxin could be detected in the crude extract, Q-Sepharose
fraction or Senshu-pack HPLC fraction.
Up to now, glucosylceramide and sterol glucoside have
been reported to exist as glucosylated forms of lipids in sphin-
golipid and cholesterol, respectively. Interestingly, they play
physiologically important roles in eukaryotic cell membranes
[29^33]. For example, Yamashita et al. [33] demonstrated that
disruption of glucosylceramide synthase halts embryonic dif-
ferentiation by the gene targeting technique. It is expected that
the new lipid described here might have potential roles in
mammalian cells, too. To understand the biological roles of
this lipid, further studies will be needed. For example, we
observed that mAb GL-1/GL-2 treatment stimulated cell
growth of BJA-B cells and cell di¡erentiation of HL60 cells
(unpublished results). If this newly found lipid is present on
the outer lea£et of the cell surface membrane, it can be ex-
pected that phosphatidylglucose may play a role in the bio-
logical processes.
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